No Place for Distress: Implementing a Simple Tool to Screen and Address Distress Symptoms in an Adult Outpatient Cancer Center by Chase, Ramona E
University of Massachusetts Amherst
ScholarWorks@UMass Amherst
Doctor of Nursing Practice (DNP) Projects College of Nursing
2016
No Place for Distress: Implementing a Simple Tool
to Screen and Address Distress Symptoms in an
Adult Outpatient Cancer Center
Ramona E. Chase
University of Massachusetts Amherst
Follow this and additional works at: https://scholarworks.umass.edu/nursing_dnp_capstone
Part of the Nursing Commons
This Open Access is brought to you for free and open access by the College of Nursing at ScholarWorks@UMass Amherst. It has been accepted for
inclusion in Doctor of Nursing Practice (DNP) Projects by an authorized administrator of ScholarWorks@UMass Amherst. For more information,
please contact scholarworks@library.umass.edu.
Chase, Ramona E., "No Place for Distress: Implementing a Simple Tool to Screen and Address Distress Symptoms in an Adult
Outpatient Cancer Center" (2016). Doctor of Nursing Practice (DNP) Projects. 59.
Retrieved from https://scholarworks.umass.edu/nursing_dnp_capstone/59
Running head: NO FOR PLACE DISTRESS: IMPLEMENTING A SIMPLE TOOL  1 
 
 
 
 
 
 
 
 
No Place for Distress: Implementing a Simple Tool to Screen and Address Distress Symptoms in 
an Adult Outpatient Cancer Center 
Ramona E. Chase 
University of Massachusetts College of Nursing 
 
 
 
 
 
 
 
Capstone Chair:    Dr. Rachel Walker 
Capstone Committee Member:  Dr. Karen Kalmakis 
Capstone Mentor:    Dr. Eliot L. Friedman 
Date of Submission:    April 30, 2016 
NO PLACE FOR DISTRESS: IMPLEMENTING A SIMPLE TOOL 2 
 
Table of Contents 
 
Abstract ................................................................................................................................3 
Introduction and Background ..............................................................................................4 
Review of the Literature ......................................................................................................6 
Theoretical Framework ......................................................................................................11 
Project Design and Methods ..............................................................................................13 
Settings and Resources ................................................................................................15 
              Description of the group, population or community ............................................16  
              Organizational analysis of project site .................................................................16 
              Evidence of stakeholder support ..........................................................................17 
              Facilitators and barriers ........................................................................................17 
       Goals, Objectives and Outcomes ................................................................................19 
       Implementation Plan ...................................................................................................20 
       Cost Analysis/Budget..................................................................................................22 
       Ethics and Human Subjects Protection .......................................................................23 
Results……………………………………………………………………………………23 
 
Discussion and Interpretation…………………………………………………………….26 
 
Limitations………………………………………………………………………………. 29 
 
Conclusion .........................................................................................................................31 
References ..........................................................................................................................32 
Appendix ............................................................................................................................37 
 
 
NO PLACE FOR DISTRESS: IMPLEMENTING A SIMPLE TOOL 3 
 
Abstract 
Background:  The Distress Thermometer (DT) is a simple and valid tool that should become the 
standard of care in the outpatient cancer setting to help clinicians better identify psychosocial 
distress at an early stage.  The purpose of the project was to implement distress screening with 
the distress thermometer (DT) with problem list (PL) to screen and address distress symptoms in 
an adult outpatient cancer center.  
Method: The distress screening pivotal visit was incorporated into the patient’s care plan at on 
day 8 on the 3rd cycle of the patients’ chemotherapy regimen. Patients graded their level of 
distress on the DT and identified the sources of their distress using the PL. A pre and post visit 
survey was done and analyzed using descriptive statistics. Pre-test and post-test DT scores were 
compared using and paired t-tests.   
Results:  A total of 83 patients received an initial distress pivotal visit and completed pre-test 
measures.  Seventy-two completed post-test measures. Paired-t test indicated an average 
reduction in distress score SD 1.76 from an average baseline score of 4.1. Paired-t test score of 
9.55 and P-value <0.0001, N =71. Of those who completed a post-test evaluation, 99% found the 
distress screening useful. 
Conclusions: Our results indicate that the DT is a simple and valid tool for measuring distress in 
this outpatient cancer setting. There are many validation studies supportive of this finding and 
encourage its use oncology clinics. However, further study may be warranted to assess long-term 
benefits of distress screening. 
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Introduction and Background 
A diagnosis of cancer can have a significant impact on patients and stimulate a cascade of 
emotional, physical and social reactions which can cause some level of distress in this patient 
population.  Distress is a significant problem experienced by a vast majority of cancer patients. It 
is an indicator of suffering, and also a predictor of poor prognosis across the disease trajectory. It 
is common and treatable (ONS, 2014).   In addition to the suffering, significant distress has been 
shown to cause dissatisfaction with care and a poor quality of life (Jacobsen & Ransom, 2007). 
Screening and early detection of distress can facilitate effective clinical intervention and 
improved patient outcome (Holland & Alici, 2010).  There is strong evidence that psychosocial, 
behavioral and pharmacologic interventions can reduce or relieve distress and help increase 
patients’ compliance with treatments and improve outcome (Jacobsen & Ransom, 2007). Yet, 
oncology healthcare clinicians may underestimate psychological distress, underdiagnose and 
undertreat this condition. As a result, the quality of care in this patient population may be 
compromised. (Holland & Alici, 2010). The purpose of the project was to implement distress 
screening with the distress thermometer (DT) with accompanying problem list (PL) to screen and 
address distress symptoms in a large adult outpatient cancer center in Lehigh Valley. 
The National Comprehensive Cancer Network (NCCN) practice guidelines for the 
Management of Psychosocial Distress, (2014) defines distress as a multifactorial distressing 
experience that may interfere with the ability to cope effectively with cancer, its physical 
symptoms, treatments and side effects extending across the continuum. The feelings range from 
vulnerability, deep sadness and fears progressing to disabling depression, anxiety, panic, social 
isolation and existential and spiritual crisis. Distress has a high prevalence in all types and stages 
of malignancies.  Needs assessment surveys with the Distress Thermometer (DT) done in 
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outpatient clinics revealed 20% - 40% of cancer patient with significant level of distress (Holland 
& Alici, 2010).  Moreover, cancer research has been successful in increasing the overall survival 
rates in this population which unfortunately leads to symptoms contributing to higher levels of 
distress (Holland & Alici, 2010).  These symptoms are many and not limited to include fatigue, 
pain, anxiety and depression, cognitive impairment such as ‘chemo brain’, nausea, vomiting, 
anorexia and fevers. These symptoms can hinder a person’s ability to perform daily activities and 
affect their quality of life (Holland & Alici, 2010).  
The prevalence of distress varies by the type of cancer and is highest among patients with 
advanced stage of disease and poor prognoses (Holland & Alici, 2010).   For example, while 
distress symptoms can be significant among patients with any cancer diagnosis, the literature 
explains that it is more often high among patients with lung cancer diagnosis. This may be so 
because lung cancer patients are often diagnosed with advanced disease and progress quickly 
through the disease trajectory. In some cases, their treatment options are also limited. As a result, 
distress is often more prevalent for lung cancer patients compared to patients with other cancer 
diagnoses. Moreover, in patients with lung cancer, family, emotional, physical symptoms, 
fatigue, depression and anxiety, pain and cognitive problems contribute to high levels of distress 
(Carlson, Walker, Groff, & Bultz, 2012).  
According to the NCCN, (2014) distress should be identified, monitored, documented 
and treated promptly at all stages of the cancer trajectory.   A gap analysis done for a large 
outpatient adult cancer center and identified a variance with current practice and 
recommendations for distress screening and management from the evidenced based literature. 
The clinical site lacked a tool specifically used for distress screening.  Instead, the clinical site 
uses a Review of System (ROS) which records any symptoms with the severity that the patient 
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experienced since the last office visit. Hence, it is not adequate in addressing the psychosocial 
needs of our patients because these symptoms are not identified with the resulting distress level 
on the patient’s psychosocial being. Therefore, the effects of these problems go undiagnosed and 
untreated. 
The American College of Surgeons (ACoS) and the Commission on Cancer (CoC) 
require cancer centers to screen for distress starting in 2015 as a new requirement for 
accreditation (ONS, 2014).   Recommendations include the development of a treatment plan with 
referrals as needed to psychosocial resources. These referrals for the assessment and distress 
management should be considered part of the patient’s routine medical oncological care, and 
should be presented to the patient as such (Pirl et al., 2015).  Distress screening is now 
considered the new standard for quality cancer care and should be integrated into the patients’ 
routine care plan (NCCN, 2014). The DT as recommended by NCCN to screen and manage 
distress will help oncology clinicians identify distress and include the appropriate management in 
their cancer care to improve patients’ compliance with their treatments, cancer outcome and 
quality of life.  In addition, this health care quality intervention satisfied at least four of the six 
IOM aims which are efficient, effective, timely and patient-centered. The DT will provide a 
means to identify ‘distress’ and incorporate the appropriate care into the patients’ care-plan, at 
the time of the visit with expedience in treatment and follow up.  At the same time it is cost 
effective since it will be incorporated into an existing medical system and is expected to improve 
patient satisfaction and outcome. 
Review of the Literature 
A comprehensive search of the literature for distress screening in cancer patients was 
completed. CINAHL and Google Scholar and PubMed databases were used with medical subject 
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headings (MeSH): Distress screening in cancer patients, distress thermometer and distress 
screening. The search yielded a total of 384 articles. Inclusion criteria were from the last 7 years 
for the most recent information, full-text articles, with subject distress thermometer. Exclusion 
criteria were greater than 7 years to eliminate older studies, pediatric patients and non-oncology 
patients. Of these 28 were selected, 14 of the 28 were selected for review. These 14 studies 
include 11 validation studies and 3 randomized controlled studies.  The validation studies looked 
at the sensitivity, specificity and validity of the DT in addition to its effectiveness over time.  
A randomized controlled trial by Carlson et al. (2012) looked at the screening of distress 
as the sixth vital sign in long cancer patients. The study not only justified the need for distress 
screening but the importance of the DT as a tool to use for screening.  The patients were 
randomized as follows: a full screening group which included the DT, Canadian problem 
checklist, pain and fatigue thermometer, and the psychological screen for cancer part C, full 
screening plus personalized triage, or a minimal screening group with the DT plus usual care.  
The participants were assessed 3 months later.  The patients were asked to rate their distress level 
on the DT and a review of diagnostic validity studies reported a pooled sensitivity of 77.1% and 
specificity of 66.1% of the DT.  The study found that screening for distress with personalized 
triage resulted in the most benefit.  In addition, they noted that the DT is meant to be used as a 
first-line screening tool that can direct the clinician to identify areas of concern for intervention. 
(Carlson, Walker, Groff, & Bultz, 2012) 
Sensitivity, Specificity and Cut-off Score of Distress Thermometer  
A study by Lazenby et al., (2014) examined the effectiveness of the DT to screen for 
distress in patients with advanced disease. There were 123 patients recruited with an average age 
of 59.9 years. All participants had stage 3 or 4 malignancies of which 40% gastrointestinal, 19% 
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gynecologic, 20% head and neck and 21% lung. The optimal distress cut-off score for clinical 
significant distress was >2/10 on the DT with a sensitivity of .96.  This result on the DT was 
compared to a score of >5/10 on the patient health questionnaire (PHQ) with a sensitivity of .32 
(Lazenby et al., 2014).  Similarly, another study by Wang et al., (2011) assesses the sensitivity 
and specificity of both the DT and the Hospital Anxiety and Depression Scale (HADS). They 
found optimal cutoff on the DT to be 4 with sensitivity of 98% and specificity of 73%.   The 
Hospital Anxiety and Depression Scale (HADS) had a cutoff score of 9 with a sensitivity and 
specificity 84% and 72% (Wang et al., 2011).  The DT had a higher sensitivity and specificity 
when compared to HADS. 
Grassi et al. (2013) also compared the DT and PL to the HADS and the 18 item brief 
symptom inventory (BSI-18).  They found that mild DT scores were 4 and 5, moderate, 6 and 7 
and DT scores >8 to be severe.  In addition, DT cutoff scores greater than or equal to 4 were 
associated with a sensitivity of 0.80 and a specificity of 0.61. These results were better than the 
BSI-18 or the HADS, and they found that the DT was a simpler and easier tool for screening 
distress. In addition, when compared to HADS the DT has a higher sensitivity and specificity 
(Wang et al., 2011).   In addition, Hegel et al. (2008) looked at the DT as a single tool for 
screening newly diagnosed breast cancer patient for distress.  They also found a DT cutoff score 
of 7 to be an optimal trade-off between a sensitivity of 0.81 and a specificity of 0.85.  Similarly, 
Bulli et al. (2009) determined that the optimal cutoff score on the DT was a 7 or above with a 
sensitivity of 0.73 and a specificity of 0.82 since they found that patients whose distress score 
was 7 or greater reported problems in all areas of the PL.  Overall these studies conclude that the 
DT showed a higher sensitivity and specificity when compared to other psychosocial screening 
tools.  In addition, the problem list identified the source of distress and the ultimate cut-off score 
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for intervention which would aid oncologist with screening.  Hence, it is an effective and simple 
tool for screening for distress symptoms in the cancer population. 
Validity and Reliability of DT 
Lazenby et al. (2014) looked at the distress thermometer as a valid tool to screen 
advanced cancer patients who are undergoing treatment for possible signs of distress. They found 
the DT to be a valid tool with good overall accuracy.  Tang et al. (2011) also tested the validation 
and reliability of the DT in a total of 574 Chinese cancer patients.  They found that a cutoff score 
on the DT was associated with an optimal sensitivity of 0.80 and specificity of 0.70 with the DT 
having a positive test-retest reliability (r =0.800, P=0.000).  They concluded that the DT was an 
acceptable tool for overall accuracy and reliability in testing distress severity and the specific 
problems causing the distress in cancer patients.  Gessler et al. (2008) and Lim et al. (2014) 
tested the DT validity and compared it to other measures like the HADS. DT was found to be a 
valid, simple quick screening tool for cancer patients.  In addition, Wang et al. (2011) supports 
the DT as a valid tool for screening distress among cancer patients since they found the DT to 
have both higher sensitivity and specificity of 98 and 73% respectively.  There are two 
guidelines chosen: The NCCN Guideline, Distress Management provided the evidenced based 
DT with PL as a valid tool for distress screening in cancer patients and the National Guideline 
Clearing House Depression in Adults guideline supports the use of the DT for screening. 
Discussion on Evidenced-Based Intervention 
All studies found a significant prevalence of distress in the cancer patient population and 
that screening is warranted for the appropriate clinical intervention to improve quality of life and 
outcome. Overall the review of the literature favors the use of the DT as a simple, quick and 
effective tool for screening distress in the cancer population. Its use is encouraged in oncology 
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clinics as it can provide the necessary information to address the causes of distress.  It was found 
consistently to have a higher sensitivity and specificity when compared to other screening tools.  
The above review of studies concluded that a cutoff DT score of 4 is sufficient to indicate 
clinical distress with 7 or greater indicating significant clinical distress requiring intervention. 
This tool is an effective means in providing a way for oncology clinicians to measure and screen 
for distress and address its physical and psychosocial symptoms while at the same time identify 
more serious treatable illnesses like depression and anxiety. In addition, DT can improve 
communication between clinician and patient. It is quick, easy to use, hence suitable for a busy 
oncology practice (Gessler et al., 2008).  
The evidence was appraised using John Hopkins Nursing Evidence-Based Practice 
(JHNEBP) for research studies (Newhouse et al., 2005) and the John Hopkins AGREE tool to 
appraise the guidelines (AGREE, 2014). The RCTs Evidence rated as Level 1, and the validation 
studies rated level II. This was considered based on randomization, adequate sample size, and 
definitive conclusions; moreover, the recommendations were consistent and based on 
comprehensive literature review. There were also guidelines used to support the DT as an 
effective tool for distress screening among oncology patients. The John Hopkins AGREE tool 
was used to assess the strength and consistency of the evidence of two guidelines, Distress 
Management and Depression in Adults with a Chronic Physical Health Problem: Treatment and 
Management.  The AGREE tool analysis found that the guidelines are of high quality.  The 
Distress Management Guideline provided the distress thermometer and problem list as an 
evidenced based tool for distress screening.  Both guidelines according to the AGREE tool 
outlined a comprehensive scope and purpose with sufficient rigor of development, applicability, 
editorial independence and clarity of presentation.  They were mostly supported with the highest 
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level of evidence through randomized controlled trials (RCT), meta-analysis, reviews of 
published meta-analysis and systematic reviews with tables to analyze the evidence.  Both 
guidelines provided clear objectives and recommendations for the management of distress, 
distressed conditions and chronic physical conditions such as depression. 
Theoretical Framework 
The process of change involves many facets and is often a difficult one to achieve with 
efficiency and success.  Using a theory guides and supports the change process to expedite and 
improve sustainability and long-term success (Zaccagnini & White, 2014).  Havelock’s Change 
Theory was chosen to guide the implementation of distress screening because of its flexibility 
and applicability to fit the paradigm of distress screening implementation in our clinical setting. 
It provides a framework as a guide to steer a successful implementation process. Appendix 2 
illustrates Havelock’s theory. Havelock and Zlotolow (1995) described a six step process to help 
individuals working in reform at all levels in diverse situations to make successful innovation 
happen.  These six stages of planned change can also be actualized through a compassionate 
approach to any specialty in health care. Havelock’s change theory outlined six specific steps 
suitable for needed change. The first stage is stage 0 which is referred to as Care. This stage 0 
raises the awareness for change. Step 1, which is called Relate, focuses on building relationships. 
In step 2, titled Examine, the problem is diagnosed and in step 3, named Acquire resources are 
identified to address the problem. During step 4, called Try, a solution to the problem is chosen. 
In step 5, called Extend, the process is disseminated, diffused, and the approval of the team is 
obtained. The final step is the Renew phase (step 6) during which implementation of the process 
is stabilized (White & Dudley-Brown, 2012). 
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Havelock’s theory describes the required six steps for successful implementation of the 
DT in our practice. For example, stage 0 recognizes that there is a need to improve the quality of 
care for cancer patients while during the Relate stage the team comes together with a common 
interest to discuss what is best for the practice and the patients. In doing so, the problem of 
distress and the need for screening and treatment for the cancer patient population is recognized.  
During the Acquire period, a gap analysis is done to examine the current system in which our 
patients received their oncological care.  Moreover, the cancer center’s inventory of resources is 
documented to address patients’ specific needs under the Acquire stage. The solution is to Try 
and implement the NCCN screening tool, the DT with PL to screen and identify the source of 
distress and address the problem to improve quality of care.  During Extend period the 
stakeholders are more involved, as the clinical experts are consulted, and cancer committee 
meetings take place to discuss topics such as proposed change, expected outcomes, building the 
change into the existing system and testing for successful implementation via patients’ pre and 
post intervention satisfaction surveys and clinicians’ collaboration and forums. Discussions for 
modifications and maintenance of change also took place. The Renew phase stabilized the 
implementation process of DT and PL. For example, there was a distress pivotal visit (DPV) 
labeled new and a distress pivotal follow up visit (DPF) at different intervals as needed subjected 
to clinicians’ discretion. The visits were billable; hence, they provided value, while they 
improved the health of the patients. At the same time, the criterion as set forth by the 
Commission on Cancer (CoC) for practice accreditation was met.  Havelock also summarizes 
three phases which frame out this implementation process: unfreezing phase, this is the initial 
phase, where the problem was identified, the stakeholders were consulted, and relationship 
building began to resolve the problem.  The moving phase, was where a plan was identified and 
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the steps taken for implementation of the DT with PL as a systematic change.  Then the 
refreezing phase, when the surveys were evaluated, and the changes were made to improve the 
QI project, and distress screening is maintained (Oates, 1997). 
Project Design and Methods 
This quality improvement project was aimed at providing oncology clinicians the 
opportunity to identify distress and provide the appropriate care to address the distress symptoms 
in cancer patients for the purpose of improving outcome and quality of life.  In order to address 
this need, we implemented a distress screening pivotal visit using the NCCN evidenced-based 
tool which consists of the distress thermometer with the accompanying problem list.  The DT 
scale range is 0 – 10 similar to the pain scale, with 0 being no distress and 10 representing 
extreme distress.  Based DT score and the source of distress as recorded on the PL 
recommendations were made by the NP according to the NCCN guidelines on distress 
management.  Overall results and outcomes of the process were evaluated using pre and post 
surveys which were analyzed using descriptive statistics and paired–t test.   
The distress screening pivotal visit took place at cycle 3 day 8 of the patients’ 
chemotherapy regiment.  Prior to the visit, a distress pivotal visit (DPV-30) and a distress pivotal 
follow up (DPF-30) were added to the patients’ existing care plans in the electronic medical 
records as a quick order. The patients were assessed by a nurse practitioner (NP) during a 
scheduled 30-minute visit. Initially, these visits were done with the DNP candidate, but once the 
process was stabilized all other outpatients NPs participated in distress screening visits with the 
physicians helping the referral process for as needed screening.  As part of documentation, there 
was a distress pivotal visit alert that was checked at the time of the initial screening visit to 
record that the patient had the distress screening. This option will also be a mode of generating 
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future reports to ensure compliance. The tool that was used is the NCCN DT with accompanying 
PL for screening which was scanned to the patient’s chart under distress screening.  A billable 
distress clinical visit followed with the desired referrals and recommendations by the DNP 
candidate. There was a pre and post survey done at the visits administered by the NP and/or a 
medical student who was present at the visit. The pre-survey provided the baseline data of 
patients’ utility of the distress screening for comparison with the post-survey data after 
intervention. The surveys also assessed patient’s acceptability and perceived benefit of the 
program.  The results were statistically analyzed using descriptive statistics and paired t test.  
Appendix 3 and Appendix 4 are illustrations of the pre and post surveys respectively. 
 A simple distress triage algorithm based on the NCCN guidelines to facilitate addressing 
distress symptoms at the distress screening visit is represented in Figure 1.  NCCN provided an 
overall guideline for managing distress symptoms (Appendix 8).  A DT score of <4 were 
assessed and documented as “no intervention needed. 
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Figure 1.  Simple Triage Algorithm for Distress symptoms at Distress Visit: 
Setting and Resources 
The distress screening and follow up visits took place in the Hematology Oncology 
outpatient office. The practice has numerous comprehensive support services available.  These 
include nurse navigators (both English and Spanish speaking), nutrition, physical therapy, 
occupational therapy, social work, psychiatric services, financial services, pain management, 
both home based and inpatient oasis-palliative care consult services, nurse practitioner managed 
survivorship PLACE (people living after cancer experience) and various multidisciplinary clinics 
(breast, lung, head and neck, genetics). Currently, in this practice some of these services were 
underused or not properly allocated due to lack of distress screening.  The above mentioned 
services and resources were utilized to the fullest with appropriate referrals made in real time to a 
social worker, psychiatrist, nutritionist and others as indicated with the distress screening 
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program.  Any physical symptoms such as diarrhea, nausea and vomiting that is the source of the 
distress were addressed by the NP at the time of visit.  This approach expedited interventions for 
physical symptoms and maximized the benefits that resulted from the DT screening program. 
Description of the population or community 
The community of interest was a large adult outpatient cancer center within the Lehigh 
Valley Physician Group known as John and Dorothy Morgan Cancer Center Hematology 
Oncology Associates.  This cancer population includes all types of malignancies except 
gynecological cancers which are treated and managed by the GYN-Oncology group. The patient 
population both male and female range in age from 25 to 99 years old of various cultural 
backgrounds.  Breast cancer is the biggest population with approximately 35% of cases, then 
lung with approximately 30%, colon and other GI cancers are approximately 20%, and all other 
malignancies which include but not limited to melanoma, kidney, sarcomas, thyroid, thymic, 
bladder, prostrate, Hodgkin’s, Leukemia and multiple myeloma averages at approximately 15%. 
Distress screening became a part of the new patients’ care plans as inclusion criteria. In addition, 
established patients were scheduled for a distress visit when their DT score recorded at routine 
office visit was greater than or equal to 4. There are no exclusion criteria as it is recommended 
by the CoC that all patient should be screened to identify their distress levels at appropriate 
intervals and as clinically indicated (NCCN, 2015).  However, for the study analysis of the DT 
implementation QI project exclusion criteria was a DT score of < 4 for established patients. All 
the patients selected had active disease and were undergoing chemotherapy treatments. 
Organizational analysis of project site.   
The project site was a large outpatient cancer center in the Lehigh Valley area.  The 
practice group is made up of 17 medical oncologists, 4 outpatient nurse practitioners, 1 inpatient 
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nurse practitioner and 4 inpatient physician assistants.  One of the physicians is the division 
chief, and one is the medical director for cancer research. There are medical assistant (MA) who 
put the patients in rooms to be seen by the provider. The medical assistants who record the 
patients’ vital signs and ROS also do patients’ blood draw for lab studies.  There are medical 
secretaries who schedule patients for their visits, referrals and checkout patients after their office 
visit.   We have two large locations and recently opened a new facility off campus to improve 
access to the rural patients.  There are two hospital based multipurpose (MP) areas attached to 
each location and a smaller offsite multipurpose area at the newest location.  Patients received 
their various chemotherapy treatments at the MP areas in addition to small procedures such as 
bone marrow biopsies, bladder instillation, intrathecal chemotherapy and intra-peritoneal 
chemotherapy treatments. The DNP candidate interacted with all facets of the multidisciplinary 
team in the office and educated the group, answered questions and acted as ongoing support to 
ensure the smooth implementation of the DT with accompanying PL. 
Evidence of stakeholder support. 
An initial presentation was made to all the practice doctors about the distress screening 
and the benefits in improving the lives of HOA cancer patients.  Once the need and the benefits 
of distress screening were described, the practice physicians, nurses and support staff supported 
the implementation of distress screening for the overall benefit of the patients and practice.  A 
stakeholder agreement in support of the project was signed. See evidence of stakeholder support 
in appendix 3. 
Facilitators and barriers. 
There were facilitators as well as barriers to implementing this project.  Having a direct 
clinical experience with the practice for more than five years allowed the opportunity to easily 
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assess the distress screening need for the practice’s patient population. There were many 
meetings with the chief of the practice who was very supportive of the project proposal. Hence, it 
was feasible to secure him as a mentor to the project. Initially, the preparation for the new 
electronic medical system placed a strained on the preparation for the implementation process. 
For example, the implementation of the electronic codes for the visits were delayed. Moreover, 
there was an initial period for testing the implementation process through a capstone study of 83 
patients with various cancer diagnoses and stages done at our two locations for various patient 
demographics.  The distress pivotal visit was done after the 3rd cycle on the 8th day of treatment 
(C3D8) unless the appointment time had to be adjusted to alleviate scheduling clashes and 
availability. 
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Table 1  
Goals and Expected Outcomes 
Goals Objectives Outcomes Achieved 
To achieve an awareness of 
the available resources for 
HOA oncology patients 
To implement the use of an 
evidence-based distress 
screening tool in an adult 
oncology population 
To provide a means where all 
our oncology clinicians can 
readily effectively screen for 
distress 
Systematic integration of 
evidence-based distress 
screening tool within 
 clinical protocols and the 
electronic medical record, 
and consistent delivery of 
these protocols across the 
targeted population 
 
To improve patients’ overall 
satisfaction with their 
oncology care in relation to 
their distress management 
To examine the effects of 
implementation of an 
evidenced-based distress 
screening tool on patients’ 
distress 
Patients who receive distress 
screening & follow-up 
reported statistically-
significant improvements in 
distress levels with 
improvement in symptoms 
Patients reported that the 
program is useful and 
acceptable.  
 
To decrease patients’ 
psychosocial distress 
associated to the cancer 
diagnosis and associated 
treatments. 
To evaluate feasibility and 
acceptability of distress 
screening in an outpatient 
oncology clinical setting 
Application for accreditation 
as stated by the Commission 
on Cancer 
The Hematology Oncology 
practice will meet criteria for 
future accreditation as a result 
of distress screening 
implementation 
 
To improve patients’ quality 
of life and compliance with 
cancer treatments 
  
 
Table 1  
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Implementation Plan 
The implementation plan involved different stages and factors coordinated for the 
implementation to be successful. There were many ongoing meetings and consultations with the 
stakeholders to determine what is best for our practice and our patients. A newly implemented 
alert immediately generated a quality check list (QCL) to the nurse practitioner’s QCL inbox 
whenever a new care plan was approved for a patient.  This alert stated “schedule for distress 
pivotal visit”.  The nurse practitioner then reviewed the chart and scheduled the visit accordingly. 
At the visit, the PL was reviewed with the patient and a DT score marked on the DT by the 
patient to indicate the level of distress. This was done with the help of the medical assistant.  A 
review of systems, a complete or focused exam was completed by the NP, and a pre-evaluation 
survey was administered by the NP or the medical student if the student was present. The source 
of distress was addressed based on the PL. Referrals were made when necessary with a follow up 
visit at the clinician’s discretion.  
This follow up visit was conducted in the same format as the initial visit and reassessed 
initial problem and new problems if needed.  At the follow up visit, there was a post-evaluation 
survey done with the patient, sometimes with the help of medical student. This post-evaluation 
survey recorded patients’ acceptability as it pertained to their improvement since their initial 
distress was addressed.  The medical record computer alert option was checked for record 
keeping and full documentation completed to the patients’ chart. The visits and services were 
billed as a level 4 or 5 depending on the nature of distress and complexity of the decision 
making.  The goal was to change practice and maintain the process for all existing and new 
patients.  Descriptive statistics and the Paired t test were used to analyze and compare the data 
collected from the pre and post surveys to compare results and measure outcome. See Appendix 3 
NO PLACE FOR DISTRESS: IMPLEMENTING A SIMPLE TOOL 21 
 
and Appendix 4 for an example of the pre and post surveys. Figure 2 below is a diagram 
illustrative of the distress screening process.  
 
 
 
 
 
    
Distress 
Screening 
 
Distress Thermometer (DT) 
And 
Problem List (PL) 
 
Consultations with main 
stakeholders 
 
Distress Pivotal Visit 
NP - 30 minutes  
Pre-Evaluation Survey 
Record DT and PL source 
Review of System and 
Exam 
Intervention / Referral 
Bill Level 4 or 5 
Use computer Alert Option  
Documentation 
Timeline 
Started after Proposal 
Approval 
 83 patients 
After 3rd cycle of 
Treatment 
 
Distress Pivotal Follow-up 
Visit 
NP - 30 minutes 
Post-Evaluation Survey 
(Monitor outcome) 
Review of systems and Exam 
Modify Intervention if 
needed 
Bill Level 3, 4, 5 
Documentation 
Change Practice 
Process maintained for all existing 
and new patients  
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Figure 2.  Distress Screening Process 
 
Cost-Benefit Analysis/Budget 
The cost for the healthcare quality project to implement a simple tool to screen and treat 
distress was minimal as it is a systematic change. There is an existing computer based 
documentation medical record.  Currently, the patients are put in rooms by the medical assistant 
who filled out the review of system with the patient. The problem list (PL) and distress 
thermometer (DT) was incorporated into this existing system with no additional cost to the 
practice.  
Cost Analysis 
 There was no new cost to the implementation of distress screening as it was a systematic 
change to the existing medical record and routine flow of the clinic.  It is more a revenue 
generating quality improvement change since the visits are billable and reimbursed by patients’ 
medical insurance plans.  Moreover, the benefits of this health care quality project cannot only 
be viewed in light of monetary gains and savings but as an added value to patients’ care, quality 
and staff satisfaction. Many studies have found that a fairly significant number of cancer patients 
experience high levels of distress.  Moreover, the prevalence of distress varies by the type of 
cancer and is highest among patients in their advanced level of disease and poor prognosis 
(Holland & Alici, 2010).  In light of this, implementation of this QI project provides a simple 
tool for oncology clinicians to identify and address this disabling symptom that seems to 
accompany patients on their cancer journey.  According to studies, implementation of this simple 
tool the DT with the PL can contribute to clinical provider-patient communication with 
improvement in patients' emotional well-being.  Screening for distress is feasible, inexpensive 
and acceptable with good patient recruitment and retention rates (Velikova, 2010).  In addition, 
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supporting patients appropriately at critical points of their cancer journey have the potential to 
reduce the development of significant psychiatric morbidity as well as cancer symptoms 
mortality (Velikova, 2010). With this formal distress screening program, oncology providers 
have the opportunity to screen and identify patients at an early stage who require assistance with 
emotional needs. They are able to provide necessary interventions that will help patients manage 
and better cope with the effects of treatment, thus improving and or maintaining their quality of 
life during cancer treatment. In some cases, patients can return to fully functional lives and 
survivorship after treatment (Velikova, 2010). 
Ethics and Human Subjects Protection 
The project was described to Institutional Review Board (IRB) for the oncology clinic as 
a QI project to be implemented on site to screen and address distress symptoms in their cancer 
patient population as required by the Commission on Cancer (CoC).  The NCCN DT and PL was 
used as our tool for distress screening.  The pre and post patient survey that were used at the 
visits were included for IRB review.  As a result, the Institutional Review Board approved the 
quality improvement project and exempted it from IRB oversight. See Appendix 5 for IRB 
correspondence letter.  
Results 
A total of 83 participants took part in the initial screening and survey study. Of these, 
36.3% were male and 63.6% were female median age of 61.2 years.  Of these participants, 31% 
had a diagnosis of breast cancer, 15% lung cancer diagnosis, 10% lymphoma disease, 11% 
diagnosis of pancreatic cancer, 8% diagnosis of colon cancer, 6% head and neck cancer diagnosis 
and 19% representative of other malignancies (Table 2).  All 83 patients received an initial 
distress pivotal visit and completed a pre-survey. There were 5 patients lost to follow up who did 
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not complete a post-survey. There were 6 surveys with missing data and were excluded from the 
analysis. Additionally, one patient completed a pre and post survey but did not include the 
distress score. Hence, this survey was also excluded from the paired-t test analysis.  Out of 77 
patients who completed a pre-survey 77% stated that their distress started since their cancer 
diagnosis, and 55% attributed their distress to physical symptoms. 
 
Table 2 
Demographic Data on Patients Screened for Distress During 
Chemotherapy Treatment 
Participants n = 77, Median Age = 61.2 years Male 36.3%, 
Female 63.6% 
Type of Cancer Percentage 
Breast 31% 
Lung 15% 
Lymphoma 10% 
Pancreatic 11% 
Colon 8% 
Head & Neck 6% 
Other 19% 
Table 2  
 
Out of 72 patients who completed pre and post-surveys, 94% reported that the causes of their 
distress were both identified and addressed, and 93% stated that their assessment was either good 
or excellent. A total of 87% reported either complete or partial resolution of distress as a result of 
this intervention. In addition, overall 99% completing both pre and post-surveys found distress 
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screening useful. The mean pre-intervention score was 4.2, and mean post intervention score was 
2.1., median score was a 2 (subjective, 0-10 scale with 0 indicating no distress and 10 
representing extreme distress). A paired-t test was conducted to compare the difference between 
the means of the pre and post-test DT scores. There was a significant difference in the scores for 
pre-test (M=4.14, SD 2.58) and post-test (M=2.14, SD=1.75) distress level; t(70 ) =9.55, p = 
<0.0001. There was a significant difference between the pre and post-test DT scores. These 
results suggest that distress screening and management have a positive effect on the patients’ 
distress level. Specifically, our results suggest that with distress screening the levels of patients’ 
distress decreased. 
Figure 3. shows a distribution of Distress Thermometer (DT) scores reported by patients 
before clinical intervention (“Pre-Intervention”, shown in heavy blue) and following clinical 
intervention (“Post-Intervention”, shown in light blue).  Figure 3. shows a shift to the left, or 
right- skewed representing lower DT scores in patients following our intervention and illustrative 
of improvement in distress. Moreover, in view of our skewed results we looked at the median 
score which indicated that the most likely post intervention distress score was a 2 which 
indicates mild distress. 
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Figure 3. Distribution of DT Scores  
 
Discussion / Interpretation 
This project was presented as an initial affirmation of the clinic’s ability to reduce the 
clinical distress experienced by the patients during their chemotherapy regimen. However, it was 
not optimum care to conduct distress screening at the routine treatment assessment and nadir 
visits due to the magnitude and complexity of stressors.  In addition, treatment visits were for the 
purpose of assessing treatment readiness and nadirs used for assessing the side effects of the 
chemotherapy treatments. Hence, we detailed our clinic’s efforts to adhere to NCCN distress 
screening management guidelines and created a designated visit for this sole purpose.  With 
distress pivotal screening visit, our patients reported reduction in their distress with screening 
and intervention. The implementation of DT was cost effective as it was a systematic change that 
was incorporated into the existing medical system. Moreover, the DT with PL implementation is 
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also revenue generating as the DPV-30 and DPF-30 are billable visits reimbursed by patients’ 
medical insurances. In addition, the DT and screening meets the requirements of the new 
guidelines set forth by the Commission of Cancer (CoC) for accreditation.  Moreover, this 
intervention is appropriate for this target population as cancer patients who are known to 
experience significant distress as a result of diagnosis and treatment.  
We found that patients were very receptive to screening and were more open to 
discussing their stressors at a designated visit for this purpose. In addition, we saw reduction in 
distress and in some cases significant reduction and better coping with cancer and chemotherapy 
treatments. Our study yielded an average of 2 points reduction in distress score which appears to 
be clinically-significant as well as statistically-significantly (P = <0.0001).   
To our knowledge evaluating this pre and post-test design with a comprehensive 
approach to distress management has not been defined in the literature.  However, many studies 
have documented that the DT is a simple, reliable and valid tool in screening patients in this 
population for distress.  For example, Tang et al., (2011) tested the validity and the reliability of 
the DT. A total of 574 Chinese cancer patients were recruited to test the validity of the DT 
relative to the Hospital Anxiety and Depression Scale (HADS) and Symptom Checklist 90 (SCL-
90). The patients with a distress score of 4 or greater that was caused by emotional problems 
were assessed using the MiNi International Neuro-psychiatric interview, another group of 106 
patients in stable condition filled out the DT at the based time and 7 – 10 days later.  They found 
that with a DT cut-off score of 4 optimal sensitivity (0.80) and specificity (0.70) relative to 
HADS with greatest sensitivity (0.87) and specificity (0.72) against SCL-90.  The study also 
showed that the DT has test-retest reliability (r=0.800, p=0.000). As with our study, after 
interventions were done for distress management patients were reevaluated using the DT.  The 
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results showed that the DT was sensitive to changes in distress levels in patients previously 
screened. Hence, the project also indicated that the DT may potentially be useful as a method or 
tool of evaluation of the impact of intervention in patients whose screening showed moderate to 
severe distress.  
In our study, the DT demonstrated reliability, efficacy and sensitivity identifying 
patients’ distress both initially and after intervention.  Gressler et al. (2008) prospective 
validation study recruited 171 outpatient oncology patients to validate the DT against HADS, 
General Health Questionnaire-12 (GHQ-12) and Brief Symptom Inventory-18 (BSI-18) initially 
and at 4 and 8 week intervals. Gressler et al. (2008) results showed that the DT changed 
significantly following the criterion measures. In addition, the results also confirmed that the DT 
can be used to monitor change in distress over time as in the test-retest reliability capability. 
Wang et al. (2011), study examined the efficacy of the HADS and the DT. They reported that 
when compared to the HADS the DT not only had higher sensitivity but the specificity was also 
higher than HADS.  Moreover, the DT’s accompanying PL was also found to be a reliable tool 
and that the physical, social, emotional and spiritual domains correlated strongly with the DT 
score (Tuinman, Gazendam-Donofrio, & Hoekstra-Weebers, 2008). As with our study, 
participants correlated their score effectively to the problem list. For example, 55% of 
participants indicated that their distress was caused by physical symptoms. After intervention for 
these symptoms patients indicated a lower distress score on the DT.  Meijer, Roseman & Delisle 
et al. (2013), state that pharmacological and behavioral interventions benefit and improve the 
distress symptoms in adult cancer patients. 
Much scientific progress has been made toward reducing the associated physical distress 
associated with cancer diagnosis and the treatment regimens. For example, targeted cell-
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therapies tend to cause reduced systemic toxicities compared to traditional chemotherapy. In 
addition, treatment delays and modifications, dose reductions, the use of supplemental medicine 
to reduce the physiological effects (such as anti-emetics and anti-diarrheal) are also incorporated 
into patients’ care plans. These advancements represent significant oncological breakthroughs, 
and the medical management of cancer as a continuous evolving specialty.  However, the cancer 
diagnosis itself can have a devastating effect on practically all facets of a person’s life.  Hence, 
the formal publication of distress screening guidelines by the NCCN represents the 
acknowledgement and the need for more action. It demonstrates the fact that physicians cannot 
always wait for further medical developments while accepting the current physical and emotional 
distress of cancer patients undergoing treatment. As a local leader in the field of healthcare, this 
large cancer center in the Lehigh Valley area has undertaken the initiative to adhere to these 
NCCN guidelines.  Hence, the design of the DT is positioned to meet the required standards for 
distress screening established by the American College of Surgeons Commission on Cancer 
effective 2015. 
Limitations 
There were some minor barriers to the DT Quality improvement project. For example, 
limited resources involved one psychiatrist available to the cancer patients who also provides 
services for non-oncology patients. This created some minor difficulty with access to psychiatric 
care and availability of appointments when urgently needed.  We were able to utilize our social 
worker to the fullest extent, and when needed, antidepressants were started by the NP sometimes 
with the physician’s guidance. Moreover, those patients with an extensive psychiatric history 
already had an established psychiatrist to whom they could easily be referred. Some administrative 
and clinical stakeholders for the project were less receptive to systematic change, and generated 
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negative feedback which states that this intervention will create too much additional workflow, or 
canceled appointments without communication or rescheduling. Moreover, there was also some 
resistance to change from the cancer support and clinical nurse specialist team who do not fully 
understand the overall goals, objectives and outcome benefits of the distress screening program 
for our patients.   This was alleviated with the support of the practice director, the chief and some 
of our physicians. In addition, there was ongoing education and questions answered by the DNP 
candidate.  The learning curve for office support staff and registered nurses was a long process. 
Another barrier was the implementation of a new electronic medical system that coincided with 
the new distress screening process. This caused some delays in the initial set up and recruitment, 
in addition to our short time period of 4 months which may have contributed to the small sample 
size.  This also posed some difficulty in navigating two systems, with one system still within a 
learning curve.  The overall distress screening visits were mostly difficult and time consuming.   
In spite of the multiple barriers encountered over the course of implementation, this project 
can boost significant strengths. The study was cost effective and well suited for the population 
intended. The outcome was well supported by the literature.  In addition, the entire process was 
quick to conduct, and patients were relatively easy to enroll. Consequently, the outcome was 
achieved in a short time after the initial intervention at the distress pivotal visit because participants 
did not require long follow up periods.  Furthermore, distress screening was implemented into an 
existing system with an established base, so it incurred no additional cost.  In some cases, patients 
with severe physical symptoms wanted to quit chemotherapy because of the side effects although 
they were responding well to treatments as indicated on their computerized tomography (CT) scan.  
However, with distress screening and interventions patients’ compliance was increased as well as 
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their survival time since they completed their treatments.  Hence, distress screening with this 
particular group provided sufficient evidence to change practice. 
Conclusions 
This study demonstrates the meaningful use of the DT with the management of cancer 
related psychosocial distress. It further shows that the DT is a simple and valid tool for 
measuring distress in an outpatient cancer setting.  It fosters compliance with utilization both on 
the patient and the clinician as well, and is noted to improve patients’ outcome.  From the 
literature review, the DT is acceptable and reliable as a screening tool to identify the contributing 
factors that cause distress severity in cancer patients which can contribute to poor outcomes. The 
DT is encouraged in oncology clinics since screening will provide the necessary information for 
oncology clinicians to identify patients at an early stage who require assistance with emotional 
needs.  We expect that our oncology clinicians will be more comfortable with providing this 
screening for our cancer population.  This distress screening program is maintained as an integral 
part of our patients’ oncology medical care to enable oncology clinicians to provide the 
necessary intervention that will help patients manage and better cope with the effects of 
diagnosis and treatment. Moreover, better management of distress in this patient population can 
improve or maintain their quality of life throughout their cancer diagnosis and treatment 
trajectory. This project primarily sought to serve the patients seen in this particular outpatient 
clinic, and secondarily, to document the change in these patients’ lives. In addition, it will 
supplement the knowledge for recommendation of distress screening to the general community 
of oncology practice. A further larger, confirming study may be needed to address the small 
sample size. In addition, there may also be a need for further study in the assessment of the 
clinical long term benefit of distress screening on the quality of life of cancer patients. 
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Appendix 1. 
Since your last office visit how distress have you been?           
 
 
 
 
 
 
 
 
     
 
 Figure 4. Distress Thermometer 
 
 
 
 
Please indicate your level of Distress on the thermometer 
And the possible cause(s) on this Problem List (PL) 
  
Practical Problems     Family 
YES     NO        YES      NO       
----      ----    Transportation   -----       -----       Children 
----      ----    Finances    -----       -----       Spouse   
----      ----    Treatment Decisions                   -----       -----       Other 
 
Physical Problems    Emotional 
-----     -----    Nausea and vomiting                 -----      -----     Depression 
-----     -----    Mouth sores                 -----      -----      Fear / Fear of reoccurrence 
-----     -----    Appetite    -----      -----      Nervousness 
-----     -----    Constipation/Diarrhea               -----      -----      Loss of interest in usual activities 
-----     -----    Physical changes   -----     -----       pain 
-----     -----    Fatigue    -----     -----       Sexuality                       
-----     -----    Chemo Brain (memory loss)      
-----     -----    Difficulty with ADLs                -----     -----      Other problems 
-----     -----    Fevers 
 
Figure 5 – Chart for problem list (PL) 
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Appendix 2. 
 
 
Figure 6.  Havelock’s Theory. Havelock & Zlotolow (1995). 
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Appendix 3. 
 
Distress Screening Pre-Evaluation Survey 
 
1. What part of your life is contributing to your distress today? 
a. Physical/Pain/Body. 
b. Relationship/Family/Social. 
c. Financial. 
d. Uncertainty about Cancer Diagnosis / Treatment Plan. 
e. Other (please explain): _________________________________. 
2. When did your current level of distress begin? 
a. Before my cancer diagnosis 
b. Since my cancer diagnosis. 
c. Since my last office visit. 
3. What is your confidence level this distress can be resolved (expectations?)? 
a. 5 (very confident). 
b. 4 (somewhat confident). 
c. 3 (neither confident nor unconfident). 
d. 2 (somewhat unconfident). 
e. 1 (completely unconfident). 
4. What are your expectations for today? 
a. 5 (complete resolution of distress). 
b. 4 (moderate resolution of distress). 
c. 3 (partial resolution of my distress). 
d. 2 (minor resolution of my distress). 
e. 1 (no resolution of my distress). 
 
 
 
 
 
Figure 7. Pre-evaluation survey 
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Appendix 4. 
Distress Screening Post- Evaluation Survey 
1. Since your last distress evaluation visit, has your level of distress: 
a. 5 (complete resolution of my distress). 
b. 4 (partial resolution of my distress). 
c. 3 (no change of my distress). 
d. 2 (some increase of my distress). 
e. 1 (large increase of my distress). 
2. At your last distress evaluation visit, do you feel as the though the causes of your 
distress were: 
a. Both Identified and Addressed. 
b. Identified Only. 
c. Neither identified nor addressed. 
3. How well did the assessment visit identify the stressors in your life? 
a. 5 (excellent). 
b. 4 (good). 
c. 3 (moderate). 
d. 2 (fair). 
e. 1 (poor). 
4. How well did the assessment visit address the stressors in your life? 
a. 5 (excellent). 
b. 4 (good). 
c. 3 (moderate). 
d. 2 (fair). 
e. 1 (poor). 
5. To what extent did you find your distress screening useful? 
a. 3 (very useful) 
b. 2 (little useful) 
c. 1 (not at all useful) 
Figure 8. Post evaluation survey 
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Appendix 5. 
 
 
 Figure 9. Stakeholder Agreement 
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Appendix 6. 
 
 
 
 
 
Figure 10. IRB Correspondence Letter 
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Appendix 7. 
  
  
  
     Human Research Protection Office  
  
      Determination of Human Subject Research  
                 Application to the Institutional Review Board  
  
The UMass Amherst IRB is required to prospectively review and approve all research involving 
human subjects.  This application helps determine if your project involves human subject 
research as defined by federal regulations.  
INSTRUCTIONS for INVESTIGATORS:  
1.  See Determining Whether IRB Review is Required for an Activity. 
2.  If the investigator is faculty, complete this form in its entirety and 
submit with any applicable survey instruments or questionnaires via 
email attachment to the Human Research Protection   
Office at humansubjects@ora.umass.edu  
If the investigator is a student, forward the completed application to 
your Faculty Sponsor for review and approval.  The Faculty Sponsor 
then submits the form with any applicable survey instruments or 
questionnaires to the HRPO via email with his or her endorsement of 
the project or activity.  
3. The UMass Amherst IRB will determine whether your research        
needs additional IRB review and notify you with a Memorandum       
of determination in an email attachment  
4. Do NOT begin data collection prior to receiving IRB 
determination    
HRPO use only  
  
  
IRB No. __________________  
Received email notification    
Emailed IRB determination    
  
☐ Project does NOT need IRB review.    
Date:  ___________________ Initials: ________  
  
☐ Project DOES need IRB review.    
Date:  ___________________ Initials: ________  
  
  
(HRPO Use Only) Determination based on following rationale:  
  
  
Investigator Information  
Investigator Name: Ramona E. Chase  UMass Affiliation: DNP student / Candidate  
Department: Nursing  Email: rhchase@umass.edu  
Faculty Sponsor (if applicable): Dr. Rachel Walker / Dr. J. Choi  Department: Nursing  
UMass Affiliation: Professor / Capstone Chair / Com. Member  Email: r.walker@umass.edu   
Project Information  
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Project Title: No Place for Distress: Implementing a Simple Tool to Screen and Address Distress  
Symptoms in an Adult Outpatient Cancer Center  
Is project supported by funding?    
☒ No  
☐ Pending * Please identify your anticipated funding source:  Click here to enter text.  
☐ Yes * Please identify your funding source:  Click here to enter text.  
   
* If federally funded, provide copy of grant proposal with this form.  
Purpose of the project:  Provide a 5-10 sentence lay description and what you hope to learn from this project To 
implement the Distress Thermometer with the problem list to screen and address distress symptoms in the 
adult hematology oncology populations. A pre and post patient survey that will not include patient identification 
information will also be used at the visits.  The survey is intended to focus on patient acceptability with the 
screening and referral process and patient perceived success with the DT with PL distress screening program.  
Describe the location where the project will take place and all project procedures:  The distress screening and 
follow up visits will take place in the Hematology Oncology outpatient office. The practice has numerous 
comprehensive support services available.  These include nurse navigators (both English and Spanish speaking), 
nutrition, physical therapy, occupational therapy, social work, psychiatric services, financial services, pain 
management, both home based and inpatient oasis-palliative care consult services, nurse practitioner managed 
survivorship PLACE (people living after cancer experience) and various multidisciplinary clinics (breast, lung, head 
and neck, genetics). The project will be an initial distress pivotal visit for patients with a distress score of 4 or 
greater and those patients with no prior screening. Patient will complete the problem list as to the source of their 
distress and indicate their level of distress on the distress thermometer. Patients will be assessed and treated 
accordingly or referred for additional services.  
  
Instructions:  Complete Section A as applicable to determine if activities in which you will be 
engaged meet the definition of human subject research.  
  
SECTION A:  Activities Determined by the UMass Amherst IRB not to Represent Human Subject 
Research 
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1.  ☐ Course-Related Activities:  The project is limited to course-related activities designed specifically for 
educational or teaching purposes where data is collected as part of a routine class exercise or assignment and 
is not intended for use outside of the classroom.  However, if students practice research methodologies on 
human beings, they should still be instructed in the ethical conduct of such activities and be advised to obtain 
informed consent from their practice subjects.   
   
NOTE: IRB approval is required if a student is involved in an activity designed to teach research methodologies and 
the instructor or student wishes to conduct further investigation and analyses in order to contribute to scholarly 
knowledge.    
2.    Oral History:  The project is limited to oral history activities, such as open ended interviews, that only 
document a specific historical event or the experiences of individuals without the intent to draw conclusions 
or generalize findings.    
NOTE: IRB approval is required when the oral history activities are intended to produce generalizable 
conclusions (e.g., that serve as data collection intended to test economic, sociological, or anthropological 
models/theories).    
3.  ☒ Journalism/Documentary Activities:  The activities are limited to investigations and interviews that 
focus on specific events, views, etc., and that lead to publication in any medium (including electronic), 
documentary production, or are part of training that is explicitly linked to journalism. There is no intent to test 
a hypothesis.  
 
   
NOTE: IRB approval may be required when journalists conduct activities normally considered scientific 
research intended to produce generalizable knowledge (e.g., systematic research, surveys, and/or interviews 
that are intended to test theories or develop models).    
4.  ☐ Information-gathering interviews:  The activity focuses exclusively on interviewing or surveying participants 
about his or her expert knowledge about products or policies rather than people or their thoughts regarding 
themselves (e.g. interviewing librarians about inter-library loan policies or rising journal costs).  
  
NOTE:  Interview questions will need to be reviewed by the HRPO.  If the activity involves collecting demographic 
information about participants it may require IRB approval.    
5.  
☐ Case Report:  The project consists of a case report or series which describes an interesting treatment, 
presentation, or outcome. A critical component is that nothing was done to the patient(s) with prior 
“research” intent.  
   
NOTE:  For case reports, HIPAA requires that the disclosure of an individual’s protected health information must be 
authorized by that individual. If a case report contains any of the 18 protected health information identifiers as 
defined by the HIPAA regulations, a signed authorization (using the authorization form from the entity that holds 
the record) to disclose this information must be obtained from the individual(s) whose information is being 
disclosed.   
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6.  ☒ Program evaluation /Quality Improvement/Quality Assurance Activities: The activity is conducted to 
assess, analyze, critique, and improve current processes within the institutional setting to include projects 
designed to improve current processes involving health care delivery in the institutional setting. The intent is not 
to generate conclusions that can be applied universally outside of the immediate environment where the project 
occurred.    
a. ☒ The activity does not involve randomization into different treatment groups.  
b. ☒ The activity is not designed to be applied to populations beyond the specific study population.  
  
Note: Quality improvement projects are designed to improve the performance of any practice in relation to an 
established standard.  Quality assurance projects are activities that are designed to determine if aspects of any 
practice are in line with established standards.  Service surveys issued or completed by University personnel for the 
purposes of improving University services/programs or for developing new services or programs for student, 
employees or alumni may fall into this category.  Investigators who plan to conduct a QI/QA project, should ensure 
that they have received approval from any applicable committees within their department or the site at which the 
activity will occur.    
7.  
☒ Evidence Based Practice Intervention:  The project or activity is designed to use best available evidence to 
make patient care decisions.  The project is focused exclusively on translating evidence and applying it to clinical 
decision-making to improve health care delivery, i.e. it is designed to close the gap between research being 
conducted and the practice.  
  
Note: “Practice” refers to interventions that are designed solely to enhance the well-being of an individual patient 
or client and that have a reasonable expectation of success.  
8.  
☒ Public Use Datasets:  The project is limited to analyzing de-identified data contained within a publicly 
available dataset. Below are examples of data sources that qualify as not human subjects research (unless the 
researcher has received restricted use data):  
   
            ☐ American National Election Studies, (ANES) 1948-2010 http://www.electionstudies.org/  
            ☐ Bureau of Economic Analysis: http://www.bea.gov/  
            ☐ Bureau of Labor Statistics (BLS): http://www.bls.gov/  
            ☐ Center for Disease Control (CDC): http://www.cdc.gov/  
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            ☐ Consumer expenditure Survey: http://www.bls.gov/cex/  
            ☐ Current Population Survey: http://www.bls.gov/cps/  
            ☐ FBI Uniform Crime Reporting Program: http://www.fbi.gov/about-us/cjis/ucr/ucr or National Archive of   
                   Criminal justice data: http://www.icpsr.umich.edu/icpsrweb/NACJD/index.jsp  
            ☐ General Social Survey: http://www3.norc.org/GSS+Website/  
            ☐ National Center for Education Statistics (NCES): http://nces.ed.gov/  
            ☐ National Longitudinal Surveys (NLS): http://www.bls.gov/nls/  
            ☐ Survey of Income and Program Participation: http://www.census.gov/sipp/  
            ☐ Government sites that bring data files together: Data.gov (http://www.data.gov/);   
FedStats (http://www.fedstats.gov/); and   
USA.gov (http://www.usa.gov/Topics/Reference_Shelf/Data.shtml) ☐ 
Other:    
  
NOTE: IRB review is required if the publicly available data set contains identifiers, or if the merging of multiple data 
sets might result in identification of the subjects. In both cases, Exempt Category #4 may apply.   
9.  ☒ De-Identified Private Information or Human Biological Specimen:  The project is limited to the use of 
existing and/or prospectively collected de-identified private information and/or human biological specimens 
(hereafter referred to as “specimens”). IRB Approval is not required if you can confirm the following:     
a. 
☒ The private information or specimens were/are not collected specifically for the currently proposed 
research project through an interaction or intervention with living individuals; and  
b. 
☒ The investigator can confirm that the use of the private information or specimens is not in violation of 
the terms of use under which the information or specimens were/will be collected; and  
c. 
☒ The investigator will only receive information or specimens that are fully de- identified. Deidentified 
means that the materials to be studied are devoid of any of the 18 Protected Health Information 
elements set forth in the Privacy Rule, as well as any codes that would enable linkage of the information 
or specimens to individual identifiers. Note: To be considered de-identified, nobody, including individuals 
who are not involved in the conduct of the project, should be able to link the information or specimens 
back to identifiers. and  
d. 
☒ Specimens are not being used to test the effectiveness of a medical device or as a control in an 
investigation of an investigational device and the results of the activity are to be submitted to the FDA or 
held for inspection by the FDA, and  
e. 
☒ The records/images/charts that are being collected for this study are not from individuals who are or 
will become recipients of an FDA regulated product (approved or experimental) or act as a control as 
directed by a research protocol and not by medical practice, and the results are to be submitted to the 
FDA or held for inspection by the FDA.  
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10.  ☒ Coded* Private Information and/or Human Biological Specimens:  The project is limited to the use of 
existing and/or prospectively collected coded private information and/or human biological specimens 
(hereafter referred to as “specimens”). IRB Approval is not required if all of the following conditions apply 
to the project:  
a. ☒ The private information or specimens were/are not collected specifically for the currently proposed 
research project through an interaction or intervention with living individuals; and  
b. ☒ The investigator(s)** cannot readily ascertain the identity of the individual(s) to whom the coded private 
information or specimens pertain because, for example:  
(1) ☒ The investigators and the holder of the key enter into an agreement prohibiting the release  
of the key to the investigators under any circumstances, until the individuals are deceased (note that HHS 
regulations do not require that the IRB review and approve this agreement);  
(2) ☒ There are IRB-approved written policies and operating procedures for a repository or data  
management center that prohibit the release of the key to the investigators under any circumstances, until 
the individuals are deceased; or  
                  (3)  ☒ There are other legal requirements prohibiting the release of the key to investigators, until             
the individuals are deceased, and  
c. ☒ Specimens are not being used to test the effectiveness of a medical device or as a control in an 
investigation of an investigational device and the results of the activity are to be submitted to the FDA or 
held for inspection by the FDA, and  
d. ☒ The records/images/charts that are being collected for this study are not from individuals who are or will 
become recipients of an FDA regulated product (approved or experimental) or act as a control as directed 
by a research protocol and not by medical practice, and the results are to be submitted to the FDA or held 
for inspection by the FDA.  
  
From the Office for Human Research Protections (OHRP) guidance document dated October 16, 2008: *Coded 
means that: (1) identifying information (such as name or social security number) that would enable the investigator 
to readily ascertain the identity of the individual to whom the private information or specimens pertain has been 
replaced with a number, letter, symbol, or combination thereof (i.e., the code); and (2) a key to decipher the code 
exists, enabling linkage of the identifying information to the private information or specimens.  
  
**Investigator includes anyone involved in conducting the research. The act of solely providing coded private information 
or specimens (for example, by a tissue repository) does not constitute involvement in the conduct of the research. If the 
individuals who provide coded information or specimens collaborate on other activities related to the conduct of this 
research with the investigators who receive such information or specimens, then the IRB would consider such additional 
activities to constitute involvement in the conduct of the research. Examples of such additional activities include, but are 
not limited to: (1) the study, interpretation, or analysis of the data resulting from the coded information or specimens; 
and (2) authorship of presentations or manuscripts related to the research.   
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11.  ☐ Decedents:  The project involves research that is limited to death records, autopsy materials, or cadaver 
specimens. If the project involves the use and/or collection of Protected Health Information (PHI), HIPAA 
regulations apply to decedent research. As the Privacy Board, the IRB Office requires that you confirm the following 
conditions as set forth in the Privacy Rule at 45 CFR 164.512(i)(ii)(iii), have been met.  
a. ☐ The use will be solely for research on the information of a decedent; and  
b. ☐ The Principal Investigator has documentation of the death of the individual about whom 
information                is being sought, and  
c. ☐ The information sought is for the purposes of the research  
  
Note, however, that this exception may not be available for decedent Information that contains Psychotherapy   
Notes or Information relating to HIV, mental health, genetic testing, or drug or alcohol abuse  
  
            ☐ Consumer expenditure Survey: http://www.bls.gov/cex/  
            ☐ Current Population Survey: http://www.bls.gov/cps/  
            ☐ FBI Uniform Crime Reporting Program: http://www.fbi.gov/about-us/cjis/ucr/ucr or National Archive of   
                   Criminal justice data: http://www.icpsr.umich.edu/icpsrweb/NACJD/index.jsp  
            ☐ General Social Survey: http://www3.norc.org/GSS+Website/  
            ☐ National Center for Education Statistics (NCES): http://nces.ed.gov/  
            ☐ National Longitudinal Surveys (NLS): http://www.bls.gov/nls/  
            ☐ Survey of Income and Program Participation: http://www.census.gov/sipp/  
            ☐ Government sites that bring data files together: Data.gov (http://www.data.gov/);   
FedStats (http://www.fedstats.gov/); and   
USA.gov (http://www.usa.gov/Topics/Reference_Shelf/Data.shtml) ☐ 
Other:    
  
NOTE: IRB review is required if the publicly available data set contains identifiers, or if the merging of multiple data 
sets might result in identification of the subjects. In both cases, Exempt Category #4 may apply.   
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9.  ☒ De-Identified Private Information or Human Biological Specimen:  The project is limited to the use of 
existing and/or prospectively collected de-identified private information and/or human biological specimens 
(hereafter referred to as “specimens”). IRB Approval is not required if you can confirm the following:     
f. 
☒ The private information or specimens were/are not collected specifically for the currently proposed 
research project through an interaction or intervention with living individuals; and  
g. 
☒ The investigator can confirm that the use of the private information or specimens is not in violation of 
the terms of use under which the information or specimens were/will be collected; and  
h. 
☒ The investigator will only receive information or specimens that are fully de- identified. Deidentified 
means that the materials to be studied are devoid of any of the 18 Protected Health Information 
elements set forth in the Privacy Rule, as well as any codes that would enable linkage of the information 
or specimens to individual identifiers. Note: To be considered de-identified, nobody, including individuals 
who are not involved in the conduct of the project, should be able to link the information or specimens 
back to identifiers. and  
i. 
☒ Specimens are not being used to test the effectiveness of a medical device or as a control in an 
investigation of an investigational device and the results of the activity are to be submitted to the FDA or 
held for inspection by the FDA, and  
j. 
☒ The records/images/charts that are being collected for this study are not from individuals who are or 
will become recipients of an FDA regulated product (approved or experimental) or act as a control as 
directed by a research protocol and not by medical practice, and the results are to be submitted to the 
FDA or held for inspection by the FDA.  
10.  ☒ Coded* Private Information and/or Human Biological Specimens:  The project is limited to the use of 
existing and/or prospectively collected coded private information and/or human biological specimens 
(hereafter referred to as “specimens”). IRB Approval is not required if all of the following conditions apply 
to the project:  
c. ☒ The private information or specimens were/are not collected specifically for the currently proposed 
research project through an interaction or intervention with living individuals; and  
d. ☒ The investigator(s)** cannot readily ascertain the identity of the individual(s) to whom the coded private 
information or specimens pertain because, for example:  
(1) ☒ The investigators and the holder of the key enter into an agreement prohibiting the release  
of the key to the investigators under any circumstances, until the individuals are deceased (note that HHS 
regulations do not require that the IRB review and approve this agreement);  
(2) ☒ There are IRB-approved written policies and operating procedures for a repository or data  
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management center that prohibit the release of the key to the investigators under any circumstances, until 
the individuals are deceased; or  
                  (3)  ☒ There are other legal requirements prohibiting the release of the key to investigators, until             
the individuals are deceased, and  
e. ☒ Specimens are not being used to test the effectiveness of a medical device or as a control in an 
investigation of an investigational device and the results of the activity are to be submitted to the FDA or 
held for inspection by the FDA, and  
f. ☒ The records/images/charts that are being collected for this study are not from individuals who are or will 
become recipients of an FDA regulated product (approved or experimental) or act as a control as directed 
by a research protocol and not by medical practice, and the results are to be submitted to the FDA or held 
for inspection by the FDA.  
  
From the Office for Human Research Protections (OHRP) guidance document dated October 16, 2008: *Coded 
means that: (1) identifying information (such as name or social security number) that would enable the investigator 
to readily ascertain the identity of the individual to whom the private information or specimens pertain has been 
replaced with a number, letter, symbol, or combination thereof (i.e., the code); and (2) a key to decipher the code 
exists, enabling linkage of the identifying information to the private information or specimens.  
  
**Investigator includes anyone involved in conducting the research. The act of solely providing coded private information 
or specimens (for example, by a tissue repository) does not constitute involvement in the conduct of the research. If the 
individuals who provide coded information or specimens collaborate on other activities related to the conduct of this 
research with the investigators who receive such information or specimens, then the IRB would consider such additional 
activities to constitute involvement in the conduct of the research. Examples of such additional activities include, but are 
not limited to: (1) the study, interpretation, or analysis of the data resulting from the coded information or specimens; 
and (2) authorship of presentations or manuscripts related to the research.   
11.  ☐ Decedents:  The project involves research that is limited to death records, autopsy materials, or cadaver 
specimens. If the project involves the use and/or collection of Protected Health Information (PHI), HIPAA 
regulations apply to decedent research. As the Privacy Board, the IRB Office requires that you confirm the following 
conditions as set forth in the Privacy Rule at 45 CFR 164.512(i)(ii)(iii), have been met.  
d. ☐ The use will be solely for research on the information of a decedent; and  
e. ☐ The Principal Investigator has documentation of the death of the individual about whom 
information                is being sought, and  
f. ☐ The information sought is for the purposes of the research  
  
Note, however, that this exception may not be available for decedent Information that contains Psychotherapy   
Notes or Information relating to HIV, mental health, genetic testing, or drug or alcohol abuse  
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11.  ☐ Decedents:  The project involves research that is limited to death records, autopsy materials, or cadaver 
specimens. If the project involves the use and/or collection of Protected Health Information (PHI), HIPAA 
regulations apply to decedent research. As the Privacy Board, the IRB Office requires that you confirm the following 
conditions as set forth in the Privacy Rule at 45 CFR 164.512(i)(ii)(iii), have been met.  
a. ☐ The use will be solely for research on the information of a decedent; and  
b. ☐ The Principal Investigator has documentation of the death of the individual about whom 
information                is being sought, and  
c. ☐ The information sought is for the purposes of the research  
  
Note, however, that this exception may not be available for decedent Information that contains Psychotherapy   
Notes or Information relating to HIV, mental health, genetic testing, or drug or alcohol abuse  
  
  
Instructions:  If your activity does not fall into the categories described in Section A, continue 
to Sections B and C to assess whether your activity is defined as research per regulations set 
forth by the Department of Health and Human Services (DHHS) and/or the Food and Drug 
Administration (FDA).  
  
Section B.  Activities Subject to HHS Human Subject Regulations (45 CFR 46)  
1.  Is the activity RESEARCH: a systematic investigation designed to contribute to generalizable knowledge?  
  
TIP: If the activity is characterized by a prospective plan that incorporates data collection, either  
quantitative or qualitative, and data analysis to answer a question and the intention of the investigation is to 
generate conclusions that can be applied universally, outside of the immediate environment where the 
investigation occurred (i.e., the classroom, hospital, department), then the activity meets the definition of  
research.  
   ☐ Yes, Go to #2                          ☒ No, Go to FDA Section C  
2.  Does the research involve obtaining information about LIVING individuals?  
    ☐ Yes, Go to #3                           ☐ No, Go to FDA Section C  
3.  Does the research involve collecting data through intervention (i.e., physical procedures or manipulation of   
the environment) or interaction (i.e., communication or interpersonal contact between investigator and 
person) with the individuals?  
 
☐ Yes, IRB review required.  ☐ No, Go to #4   
Go to FDA section C to assess if  
           FDA regulations apply to your study.  
4.  Does the research involve collecting identifiable information (i.e., the identity of the subject is or may 
readily be ascertained by the investigator or associated with the information)?  
 ☐  Yes, Go to #5  ☐  No, Go to FDA Section C  
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5.  Is the information private? (About behavior that occurs in a context in which an individual can reasonably 
expect that no observation or recording is taking place, or provided for specific purposes by an individual and 
which the individual can reasonably expect will not be made public)  
 ☐ Yes, IRB review required  ☐ No, Go to FDA Section C  
Go to FDA section C to assess if  
FDA regulations apply to your study.  
  
Section C.  Activities Subject to FDA Human Subject Regulations:  If your answer is “yes” to any of the 
thre questions below, IRB approval is required and the FDA regulations apply to your study.  
1.   Is this is an experiment that involves a test article * and one or more human subjects, and the results of which 
are intended to be later submitted to, or held for inspection by, the FDA as part of an application for a research or 
marketing permit? A subject is an individual (either health or a patient) who is a recipient of the test article or a 
control.  
   
*Test article Test article means any drug (including a biological product for human use), medical device for 
human use, human food additive, color additive, electronic product, or any other article subject to regulation 
under the Food, Drug, and Cosmetic Act.  
☐ Yes, IRB review required                                      ☒ No  
2.   Is this is a clinical investigation or research involving one or more human subjects to determine the safety 
or effectiveness of a device? A subject is an individual (healthy or has a medical condition or disease) on 
whom or on whose specimen an investigational device is used, or who participates as a control.  
☐ Yes, IRB review required                                       ☒ No  
3.  Is this an experiment in which a drug is administered or dispensed to, or used involving, one or more human 
subjects? This excludes the use of a marketed drug in the course of medical practice. A human subject is an 
individual (healthy or patient with a disease) that participates either as a recipient of the investigational new drug or 
as a control.  
☐  Yes, IRB review required                                       ☒  No  
Instructions:  If IRB review is required, you must submit a NEW STUDY application to the IRB in e-protocol.  
  
Section D.  Investigator Responsibilities and Assurances  
• I certify that the information provided in this determination form and in all attachments is complete and 
accurate.  
• I understand that I have ultimate responsibility for the protection of the rights and welfare of human 
participants and for the ethical conduct of this activity.  
• If determined to meet the regulatory definition of human subject research, I agree to comply with all UMass 
Amherst policies and procedures, the terms of its Federal-wide Assurance, and all applicable federal, state, 
and local laws regarding the protection of human participants in research.  
• I certify that the proposed project has not yet been done, is not currently underway, and will not begin until 
IRB determination and/or approval has been obtained.  
  
Investigator Signature  
Name: Ramona E. Chase  
  
Date: 10/16/2015  
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Figure 11. UMass IRB Application 
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Appendix 8 
 
 
 
 
 
Figure 12. NCCN Guidelines for Distress Management 
 
 
 
 
 
 
 
